ArticleScientific reports2025
Neuroprotective and intraocular pressure lowering effects of dual-functional memantine nitrate MN-08 on the experimental models of glaucoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Lycium barbarum polysaccharide as a retinoprotective agent: A meta-analysis of preclinical evidence from rodent models of retinopathy.Neural regeneration research · 2026Article
- Neurotoxic effects of dietary glutamate in glaucoma and potential nutritional and pharmacological therapies: a scoping review.International ophthalmology · 2026Article
- Retinal Ganglion Cell Degeneration in Glaucoma: Systematic Review.Bioengineering (Basel, Switzerland) · 2026Review
- Dual-functional nanoparticle formulations for simultaneous intraocular pressure reduction and neuroprotection in glaucoma: a review.Nanomedicine (London, England) · 2026Review
- Microglial regulation of synaptic plasticity in transsynaptic degeneration of glaucoma.Frontiers in neuroscience · 2026Review
- Next-Gen Neuroprotection in Glaucoma: Synergistic Molecules for Targeted Therapy.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Glaucoma stands out as the primary cause of permanent blindness worldwide, marked by elevated intraocular pressure (IOP) and the deterioration of retinal ganglion cells (RGCs) within the optic nerve. This study aimed to investigate the therapeutic efficacy of MN-08, a novel memantine nitrate derivative, in experimental models of glaucoma. In the rat model of retinal ischemia-reperfusion injury, MN-08 prevented the reduction in retinal ganglion cell complex (GCC) thickness and RGC loss. Meanwhile, MN-08 reduced the protein levels of cleaved-caspase-3, caspase-3, and Bax, while increasing the expression of Bcl-2 compared to the model group, indicating that MN-08 exerts an inhibitory effect on the apoptosis of RGCs. Furthermore, MN-08 lowered IOP in the transient ocular hypertension and glaucoma rabbit models. MN-08 significantly increased cGMP levels in human trabecular meshwork cells (HTMCs). Elevation of cGMP induced by MN-08 was eliminated by ODQ. Moreover, MN-08 attenuated the protein levels of MLCK and p-MLC-2 in HTMCs induced by endothelin-1. Additionally, MN-08 exhibited favorable distribution profiles and pharmacokinetic parameters in normal rabbit ocular tissues following topical instillation. These findings indicate that MN-08 could antagonize NMDA receptors to protect RGCs and release NO to relax TM for the treatment of glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.